Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

BDNF genetic variants and methylation, effects on cognition in major depressive disorder

  • Ferrer, Alex|||0000-0002-3040-1177
  • Labad, Javier|||0000-0003-2214-1886
  • Salvat-Pujol, Neus|||0000-0001-5320-331X
  • Barrachina, Marta
  • Costas, Javier|||0000-0003-0306-3990
  • Urretavizcaya, Mikel|||0000-0002-9746-4068
  • De Arriba-Arnau, Aida|||0000-0002-7877-7341
  • Crespo, José M.
  • Soriano-Mas, Carles|||0000-0003-4574-6597
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Menchón Magriñá, José Manuel|||0000-0002-6231-6524
  • Soria, Virginia|||0000-0001-6412-6831
Brain-derived neurotrophic factor (BDNF) gene regulation has been linked to the pathophysiology of major depressive disorder (MDD). MDD patients show cognitive deficits, and altered BDNF regulation has a relevant role in neurocognitive functions. Our goal was to explore the association between BDNF genetic and epigenetic variations with neurocognitive performance in a group of MDD patients and healthy controls considering possible modulating factors. The sample included 134 subjects, 64 MDD patients, and 70 healthy controls. Clinical data, childhood maltreatment, and neurocognitive performance were assessed in all participants. Eleven single nucleotide polymorphisms (SNPs) and two promoter regions in the BDNF gene were selected for genotype and methylation analysis. The role of interactions between BDNF genetic and epigenetic variations with MDD diagnosis, sex, and Childhood Trauma Questionnaire (CTQ) scores was also explored. We observed significant associations between neurocognitive performance and two BDNF SNPs (rs908867 and rs925946), an effect that was significantly mediated by methylation values at specific promoter I sites. We identified significant associations between neurocognitive results and methylation status as well as its interactions with MDD diagnosis, sex, and CTQ scores. Our results support the hypothesis that BDNF gene SNPs and methylation status, as well as their interactions with modulating factors, can influence cognition. Further studies are required to confirm the effect of BDNF variations and cognitive function in larger samples.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sex-specific association between the cortisol awakening response and obsessive-compulsive symptoms in healthy individuals

  • Melia, Cristian Sebastian|||0000-0001-6784-4185
  • Soria, Virginia|||0000-0001-6412-6831
  • Salvat-Pujol, Neus|||0000-0001-5320-331X
  • Cabezas, Ángel|||0000-0001-8114-0264
  • Nadal i Alemany, Roser|||0000-0001-8972-2525
  • Urretavizcaya, Mikel|||0000-0002-9746-4068
  • Gutiérrez-Zotes, Alfonso|||0000-0002-4858-1487
  • Monreal Ortiz, Jose Antonio|||0000-0002-0906-927X
  • Crespo, José Manuel
  • Alonso, Pino|||0000-0002-5779-9111
  • Vilella, Elisabet|||0000-0002-1887-5919
  • Palao, Diego|||0000-0002-3323-6568
  • Menchón Magriñá, José Manuel|||0000-0002-6231-6524
  • Labad, Javier|||0000-0003-2214-1886
Previous studies have shown associations between obsessive-compulsive disorder (OCD) and hypothalamic-pituitary-adrenal axis activity (HPA). We aimed to investigate the association between obsessive-compulsive (OC) symptoms and HPA axis functionality in a non-clinical sample and to explore whether there are sex differences in this relationship. One hundred eighty-three healthy individuals without any psychiatric diagnosis (80 men, 103 women; mean age 41.3 ± 17.9 years) were recruited from the general population. The Obsessive-Compulsive Inventory Revised (OCI-R) was used to assess OC symptoms. State-trait anxiety, perceived stress, and stressful life events were also assessed. Saliva cortisol levels were determined at 6 time points (awakening, 30 and 60 min post-awakening, 10:00 a.m., 23:00 p.m. and 10:00 a.m. the following day of 0.25 mg dexamethasone intake [that occurred at 23:00 p.m.]). Three HPA axis measures were calculated: cortisol awakening response (CAR), cortisol diurnal slope, and cortisol suppression ratio after dexamethasone (DSTR). Multiple linear regression analyses were used to explore the association between OC symptoms and HPA axis measures while adjusting for covariates. Our main analyses were focused on OCI-R total score, but we also explored associations with specific OC symptom dimensions. No significant differences were observed between males and females in OC symptoms, anxiety measures, stress, or cortisol measures. In the multiple linear regression analyses between overall OC symptoms and HPA axis measures, a female sex by OC symptoms significant interaction (standardized beta = - 0.322; p = 0.023) for the CAR (but not cortisol diurnal slope nor DSTR) was found. Regarding specific symptom dimensions, two other sex interactions were found: a blunted CAR was associated with obsessing symptoms in women, whereas a more flattened diurnal cortisol slope was associated with ordering symptoms in men. There are sex differences in the association between OC symptoms and HPA axis measures in healthy individuals.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Role of Sleep Quality, Trait Anxiety and Hypothalamic-Pituitary-Adrenal Axis Measures in Cognitive Abilities of Healthy Individuals

  • Labad, Javier|||0000-0003-2214-1886
  • Urretavizcaya, Mikel|||0000-0002-9746-4068
  • Monreal Ortiz, Jose Antonio|||0000-0002-0906-927X
  • Crespo, José Manuel
  • Vilella, Elisabet|||0000-0002-1887-5919
  • Palao, Diego|||0000-0002-3323-6568
  • Menchón Magriñá, José Manuel|||0000-0002-6231-6524
  • Soria, Virginia|||0000-0001-6412-6831
  • Salvat-Pujol, Neus|||0000-0001-5320-331X
  • Armario Garcia, Antonio|||0000-0001-9524-3635
  • Cabezas, Ángel|||0000-0001-8114-0264
  • De Arriba-Arnau, Aida|||0000-0002-7877-7341
  • Nadal i Alemany, Roser|||0000-0001-8972-2525
  • Martorell, Lourdes|||0000-0003-4999-2197
Sleep plays a crucial role in cognitive processes. Sleep and wake memory consolidation seem to be regulated by glucocorticoids, pointing out the potential role of the hypothalamic-pituitary-adrenal (HPA) axis in the relationship between sleep quality and cognitive abilities. Trait anxiety is another factor that is likely to moderate the relationship between sleep and cognition, because poorer sleep quality and subtle HPA axis abnormalities have been reported in people with high trait anxiety. The current study aimed to explore whether HPA axis activity or trait anxiety moderate the relationship between sleep quality and cognitive abilities in healthy individuals. We studied 203 healthy individuals. We measured verbal and visual memory, working memory, processing speed, attention and executive function. Sleep quality was assessed with the Pittsburgh Sleep Quality Index. Trait anxiety was assessed with the State-Trait Anxiety Inventory. HPA axis measures included the cortisol awakening response (CAR), diurnal cortisol slope and cortisol levels during the day. Multiple linear regression analyses explored the relationship between sleep quality and cognition and tested potential moderating effects by HPA axis measures and trait anxiety. Poor sleep quality was associated with poorer performance in memory, processing speed and executive function tasks. In people with poorer sleep quality, a blunted CAR was associated with poorer verbal and visual., memory and executive functions, and higher cortisol levels during the day were associated with poorer processing speed. Trait anxiety was a moderator of visual memory and executive functioning. These results suggest that subtle abnormalities in the HPA axis and higher trait anxiety contribute to the relationship between lower sleep quality and poorer cognitive functioning in healthy individuals.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Childhood maltreatment interacts with hypothalamic-pituitary-adrenal axis negative feedback and major depression, effects on cognitive performance

  • Salvat-Pujol, Neus|||0000-0001-5320-331X
  • Labad, Javier|||0000-0003-2214-1886
  • Urretavizcaya, Mikel|||0000-0002-9746-4068
  • De Arriba-Arnau, Aida|||0000-0002-7877-7341
  • Segalàs, Cinto|||0000-0002-0959-0356
  • Real, Eva|||0000-0003-4523-1649
  • Ferrer, Alex|||0000-0002-3040-1177
  • Crespo, José M.
  • Jiménez Murcia, Susana|||0000-0002-3596-8033
  • Soriano-Mas, Carles|||0000-0003-4574-6597
  • Menchón Magriñá, José Manuel|||0000-0002-6231-6524
  • Soria, Virginia|||0000-0001-6412-6831
Background : Childhood maltreatment (CM) is associated with impaired hypothalamic-pituitary-adrenal (HPA) axis negative feedback and cognitive dysfunction, resembling those abnormalities linked to major depressive disorder (MDD). Objectives : We aimed to assess the potential modulating effects of MDD diagnosis or HPA axis function in the association between different types of CM and cognitive performance in adulthood. Methods : Sixty-eight MDD patients and 87 healthy controls were recruited. CM was assessed with the Childhood Trauma Questionnaire. We obtained three latent variables for neuropsychological performance (verbal memory, visual memory and executive function/processing speed) after running a confirmatory factor analysis with cognitive tests applied. Dexamethasone suppression test ratio (DSTR) was performed using dexamethasone 0.25 mg. Results : Different types of CM had different effects on cognition, modulated by MDD diagnosis and HPA axis function. Individuals with physical maltreatment and MDD presented with enhanced cognition in certain domains. The DSTR differentially modulated the association between visual memory and physical neglect or sexual abuse. Conclusions : HPA axis-related neurobiological mechanisms leading to cognitive impairment might differ depending upon the type of CM. Our results suggest a need for early assessment and intervention on cognition and resilience mechanisms in individuals exposed to CM to minimize its deleterious and lasting effects. HIGHLIGHTS • We studied the effects of childhood maltreatment (CM), HPA axis feedback (DST), and depression on cognition. • Different types of CM had a distinct impact on cognitive performance. • MDD diagnosis and DST modulated the association between CM and cognition.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Relationship between immunometabolic status and cognitive performance among major depression disorder patients

  • Sánchez-Carro, Yolanda
  • Torre-Luque, Alejandro de la|||0000-0003-0595-6127
  • Portella Moll, Maria J., 1975-|||0000-0002-2007-9516
  • Leal-Leturia, Itziar|||0000-0002-4384-1307
  • Salvat-Pujol, Neus|||0000-0001-5320-331X
  • Massaneda, Clara
  • De Arriba-Arnau, Aida|||0000-0002-7877-7341
  • Urretavizcaya, Mikel|||0000-0002-9746-4068
  • Peretó, Mar
  • Toll, Alba|||0000-0003-2399-5250
  • Martínez-Ruiz, Antonio
  • Ferreiros-Martinez, Raquel
  • Álvarez, Pilar
  • Soria, Virginia|||0000-0001-6412-6831
  • López-García, Pilar
Background: Alterations in cognitive performance have been described in patients with major depressive disorder (MDD). However, the specific risk factors of these changes are not yet known. This study aimed to explore whether inmunometabolic parameters are related to cognitive performance in MDD in comparison to healthy controls (HC) Methods: Sample consisted of 84 MDD patients and 78 HC. Both groups were compared on the results of cognitive performance measured with the Cambridge Neuropsychological Test Automated Battery (CANTAB), the presence of metabolic syndrome (MetS) and an inflammatory/oxidative index calculated by a principal component analysis of peripheral biomarkers (tumor necrosis factor, C-reactive protein and 4-hydroxynonenal). A multiple linear regression was carried out, to study the relationship between inmunometabolic variables and the global cognitive performance, being the latter the dependent variable. Results: Significant differences were obtained in the inflammatory/oxidative index between both groups (F= 12.93; p <.001), also in cognitive performance (F= 56.75; p <.001). The inmunometabolic covariate regression model (i.e., condition (HC/MDD), sex, age and medication loading, MetS, inflammatory/oxidative index and the interaction between MetS and inflammatory/oxidative index) was statistically significant (F= 11.24; p <.01) and explained 31% of variance. The condition, being either MDD or HD, (B=˗0.97; p <.001), age (B=˗0.28; p <.001) and the interaction between inflammatory/oxidative index and MetS (B=˗0.38; p =.02) were factors associated to cognitive performance. Limitations: Sample size was relatively small. The cross-sectional design of the study limits the possibilities of analysis. Conclusions: Our results provide evidence on the conjoint influence of metabolic and inflammatory dysregulation on cognitive dysfunction in MDD patients. In this way, our study opens a line of research in immunometabolic agents to deal with cognitive decline associated with MDD.